Inactive Instrument

Insiders Sarepta Therapeutics Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

14/05	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	MT
02/05	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	MT

Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	12/03	MT
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	07/03	MT
Sarepta Therapeutics Insider Bought Shares Worth $2,001,800, According to a Recent SEC Filing	06/11	MT
Sarepta Therapeutics Insider Bought Shares Worth $3,940,500, According to a Recent SEC Filing	06/11	MT
Insider Buy: Sarepta Therapeutics	15/23/15	MT
Insider Buy: Sarepta Therapeutics	14/23/14	MT
Insider Buy: Sarepta Therapeutics	11/23/11	MT
Insider Sell: Sarepta Therapeutics	09/23/09	MT
Sarepta Therapeutics, Inc. Announces Executive Changes	03/22/03	CI
Insider Buy: Sarepta Therapeutics	15/22/15	MT
Insider Buy: Sarepta Therapeutics	22/22/22	MT
Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors	03/22/03	CI
Editas Medicine Appoints Sarepta Therapeutics Executive Gilmore O'Neill as CEO	14/22/14	MT
Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director	06/22/06	CI
Insider Buy: Sarepta Therapeutics	30/21/30	MT
Sarepta Therapeutics Names Louise Rodino-Klapac as Head of Research and Development	17/21/17	CI
Sarepta Therapeutics Appoints Stephen L. Mayo to Its Board of Directors	17/21/17	CI
Selecta Biosciences : Names Kevin Tan Finance Chief	20/21/20	MT
Selecta Biosciences : Hires Kevin Tan as CFO	20/21/20	MT
Sarepta Therapeutics, Inc. Elects Ryan Brown as General Counsel	02/21/02	CI

No results for this search